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ABSTRACT

Human papillomavirus (HPV) is the most common sexually transmitted infection
in the United States, but few studies have examined the progression from HPV infection
to disease in men. Genital condyloma are the most common clinical manifestation of
HPV infection. Though not associated with mortality, condyloma are a source of
emotional distress, and treatment is often painful with a high recurrence rate. The aims
of this study were to examine the distribution of HPV types present on the surface of
condyloma, estimate the incidence of condyloma overall and after type-specific HPV
infections, assess the sociodemographic and sexual behavior factors independently
associated with incident condyloma, and examine the concordance between HPV types
detected on the surface and in the tissue of condyloma. Participants included 2,487
men from the United States, Brazil, and Mexico who were enrolled in the prospective
HPV in Men (HIM) Study and followed every six months for up to four years. At each
study visit men completed a computer-assisted-self-administered risk factor
questionnaire and samples of healthy penile skin were obtained to test for HPV DNA. A
trained clinician examined men for the presence of condyloma and swabbed the surface
of lesions to test for HPV DNA. Men were followed for a median of 17.9 months and 112
incident condyloma were identified. Thirty-four external genital lesions were also
biopsied to test for HPV within the lesion tissue. PCR was used to test for HPV DNA
and Linear Array was used to genotype 13 oncogenic and 24 non-oncogenic HPV types
in samples obtained from swabbing the lesion surface. The LiPa assay was used to
genotype 20 HPV types in biopsy samples. The Kaplan-Meier method was used to
estimate incidence and Cox proportional hazards models were used to examine factors
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independently associated with incident condyloma. Using biopsy samples as the gold
standard, sensitivity and specificity were calculated to examine concordance between
HPV types detected on the surface and within the tissue of condyloma. Condyloma
incidence was 2.35 per 1,000 person-years. HPV 6 (43.8%), 11 (10.7%), and 16 (9.8%)
were the most common types detected on condyloma. The probability of developing
condyloma within 24-months of an incident HPV 6/11 infection was 14.6% (95%
confidence interval (CI): 7.5-21.1). The median time to condyloma development was
17.1 months (95% CI: 12.4-19.3), with the shortest time to detection observed among
men with incident HPV infections with types 6/11 only (6.2 months; 95% CI: 5.6-24.2).
Factors associated with condyloma were incident HPV 6/11 infection (hazard ratio
(HR)=12.42; 95% CI: 3.78-40.77), younger age (HR=0.43; 95% CI: 0.26-0.77; 45-70 vs.
18-30 years), high lifetime number of female partners (HR=5.69; 95% CI: 1.80-17.97);
≥21 vs. 0), and sexual behaviors in the previous three months including infrequent
condom use (HR=2.44; 95% CI: 1.16-5.14; <half the time vs. always), number of male
sexual partners (HR=4.53; 95% CI: 1.68-12.20; ≥3 vs. none), frequent vaginal
intercourse (HR=4.14; 95% CI: 1.32-13.01); ≥21 times vs. none), having a partner with
condyloma (HR=2.38; 95% CI: 1.01-5.61), and being diagnosed with a sexually
transmitted infection (HR=1.99; 95% CI: 1.17-3.39). HPV 6/11 plays an important role in
condyloma development with the highest incidence and shortest time to condyloma
development observed among men with incident HPV 6/11 infections. Recent sexual
history was also strongly associated with incident condyloma in men, suggesting that
prevention efforts targeting behavioral modification may be effective at reducing
condyloma incidence among men who are not vaccinated. Samples obtained from the
surface of condyloma lesions were both sensitive and specific as markers for the
presence of any HPV, HPV6 and HPV11 in condyloma tissue, suggesting that sampling
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the surface of condyloma is a non-invasive and accurate marker of the HPV types
present within the tissue.

vii

CHAPTER 1: INTRODUCTION

STUDY PURPOSE
Human papillomavirus (HPV) is the most common sexually transmitted infection
in the United States (US), with an estimated 6.2 million new cases each year [1]. HPV is
an established cause of cervical cancer and is also associated with cancers of the
oropharynx, anus, penis, vulva and vagina [2]. Over 100 HPV types have been
identified and approximately 40 of these types infect the anogenital region. HPV types
are classified as oncogenic types (e.g. 16, 18, 31, and 45) that are associated with
intraepithelial neoplasia and invasive carcinoma, and non-oncogenic types (e.g. 6 and
11) that are associated with benign conditions such as condyloma.
Estimates of the prevalence of HPV in men has been as high as 73%. Recent
studies of men in the US have reported that approximately 50% of men are positive for
at least one known HPV type, and an additional 10-15% are positive for one or more
unknown HPV types [3-5]. The probability of acquiring a new HPV infection over a 12month period is 29-39% [3, 5, 6]. Incidence of HPV infection is not associated with age
in men and remains consistent across the lifespan [3].
The majority of HPV infections are asymptomatic with an estimated 70% of
incident infections clearing within one year [7]. Persistent infections can progress to
disease and anogenital condyloma is the most common clinical manifestation of HPV
infection [8]. Though condyloma are not associated with mortality, they are a source of
physical discomfort, emotional distress and reduced quality of life [9, 10]. Condyloma
have a high transmission rate between sexual partners; approximately 65% of
individuals who have a sexual partner with condyloma will develop condyloma
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themselves [11]. Treatment is often ineffective with about one-fourth of cases recurring
within 3 months of treatment [12]. The high recurrence rate is associated with high
medical costs; approximately $200 million is spent annually in the US to treat condyloma
[13].
The quadrivalent vaccine Gardasil, which protects against HPV types 6, 11, 16,
and 18, was approved in October 2009 by the U.S. Food and Drug Administration for
use in males ages 9 to 26. Clinical trials have shown the vaccine to be effective at
reducing the incidence of HPV infection and condyloma in men ages 16-26 [14].
Incidence rates of condyloma and estimates of time from HPV infection to condyloma
detection are necessary parameters for modeling the effectiveness of prevention through
vaccination.
To date, most research on the progression of HPV infection to disease has
focused on women. Little is known about the natural history of HPV related disease in
men, including incidence of condyloma, the prevalence of HPV types within condyloma,
the proportion of type-specific HPV infections that progress to condyloma, and the time
from an HPV infection to development of condyloma. Since male genital lesions are
reservoirs for HPV infection, understanding the natural history of HPV related genital
disease in men has the potential to not only reduce the burden of male disease, but also
reduce the rate of HPV transmission to women.
Current incidence rates for condyloma among US men are based on data from
private insurance claims [15-17]. These data likely underestimate true incidence since
they exclude individuals who do not seek treatment or who are not privately insured.
Likewise, little is known regarding the median time from HPV infection to condyloma
detection with only one published study to date conducted among young university
students positive for HPV 6/11 [18]. Likewise, only a few studies have examined sexual
behavioral factors associated with the development of condyloma in men [19-22], and
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most of these studies were among highly selective populations including STI clinic
attendees [20, 21] and men who have sex with men [22]. Similarly, many studies
examining risk factors for condyloma in women have also been in select populations
such as university students [23], STI clinic attendees [20], and young women in the
placebo arm of an HPV vaccine trial [24]. Given that treatment of condyloma is often
ineffective, it is important to identify modifiable behavioral factors for prevention efforts,
especially among individuals who do not receive vaccination.
Sampling methods can influence prevalence estimates of HPV types present in
condyloma. Current standard practice is to diagnose condyloma by visual inspection,
and biopsy samples are not often obtained to confirm the diagnosis [25]. As a result,
studies that include individuals from a standard clinic setting sample the surface of
condyloma lesions to estimate the prevalence of HPV genotypes in the lesion tissue [2628]. It is possible that the HPV types detected on the surface of lesions may not
represent the types present in the lesions themselves. Assessing whether sampling the
surface of a condyloma lesion provides an accurate measure of the HPV types present
within the tissue of the condyloma could provide support as to whether it is necessary to
biopsy a condyloma to accurately estimate the prevalence of HPV types in the lesion.

SPECIFIC AIMS
The goal of this research is to examine the progression of HPV infection to
condyloma development in men. The proposed research will be based on a sub-cohort
of 2,487 men enrolled in the HPV in Men (HIM) Study. The HIM Study is a prospective
study that examines the natural history of anogenital HPV infection in men ages 18-70
from the US, Brazil, and Mexico. The specific aims of this research are:
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1. Estimate the incidence of condyloma, describe the prevalence of HPV types detected
in incident condyloma and measure the time from type specific incident HPV
infections to condyloma detection.
2. Identify sociodemographic and sexual behavioral factors associated with the
incidence of condyloma.
3. Examine the concordance between HPV types detected on the surface and in the
tissue of histologically confirmed anogenital condyloma.
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CHAPTER 2: FIRST MANUSCRIPT: INCIDENCE AND HPV TYPE DISTRIBUTION OF
CONDYLOMA IN A MULTINATIONAL COHORT OF MEN: THE HIM STUDY

ABSTRACT
Background: Data on the natural history of human papillomavirus (HPV) infection
progression to genital warts (GW) in men are sparse. We described the distribution of
HPV types in incident GW and estimated GW incidence and time from type-specific
incident HPV infections to GW detection in a multinational cohort of men ages 18-70.
Methods: Participants included 2,487 men examined every 6 months and followed for a
median of 17.9 months. Samples obtained from 112 incident GW were tested for HPV
DNA by PCR. Genotyping tested for the presence of 37 HPV types.
Findings: Incidence of GW was 2.35 per 1,000 person-years with the highest incidence
rate observed among men ages 18-30 (3.43 per 1,000 person-years). HPV 6 (43.8%),
11 (10.7%), and 16 (9.8%) were the most common types detected in GW. The 24 month
cumulative incidence of GW among men with incident HPV 6/11 infections was 14.6%
(95% CI: 7.5-21.1). The median time to any GW detection was 17.1 months (95% CI:
12.4-19.3), with the shortest time to detection observed among men with incident
infections with HPV 6/11 only (6.2 months; 95% CI: 5.6-24.2).
Interpretation: HPV 6/11 plays an important role in GW development with the highest
incidence and shortest time to GW development observed among men with incident
HPV 6/11 infections.
Funding: National Cancer Institute.
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INTRODUCTION
Anogenital human papillomavirus (HPV) is the most common sexually
transmitted infection in the United State (US) [1]. Over 100 HPV types have been
identified and approximately 40 of these infect the anogenital region. Genital warts
(GW) are a common HPV related disease associated with HPV types 6 and 11 [12]. In
the US, 5.6% of sexually active adults ages 18-59 have self-reported ever being
diagnosed with GW [29] and 1% of US adults ages 18-45 are estimated to have GW at
any given time [30]. Though GW are benign and not associated with mortality, they are
a source of psychosocial distress [9] and can cause physical discomfort including pain,
bleeding and itching [25]. GW are highly infectious; 65% of people who have sex with a
partner with GW will develop GW themselves [11]. A high rate of recurrence makes
treatment difficult and costly [31]. Approximately $200 million is spent annually in the US
for GW treatment [13].
HPV vaccination may be an effective approach for primary prevention of GW
[32]. However, incidence rates for GW and estimates of time from HPV infection to GW
detection are necessary parameters for modeling the effectiveness of GW prevention
through vaccination. Few published studies have reported the HPV type distribution in
GW [26-28, 33], the incidence of GW [15-17], and the time from HPV infection to GW in
men [18]. Most published incidence rates of GW for US men are based on data from
private insurance claims [15-17]. These data likely underestimate true incidence since
they exclude individuals who do not seek treatment or who are not privately insured.
Likewise, little is known regarding the median time from HPV infection to GW detection
with only one published study to date conducted among young university students
positive for HPV 6/11 [34].
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The purpose of this study was to describe the prevalence of HPV types detected
in newly acquired GW and estimate GW incidence and time from type specific incident
HPV infections to GW detection in a multinational cohort of men ages 18-70.

METHODS
Study population
The HPV in Men (HIM) Study is a multinational prospective study of men ages
18-70 that examines the natural history of HPV infection in men. Participants were
enrolled into the HIM Study between July 2005 and September 2009 and met the
following inclusion criteria: (a) 18-70 years old; (b) resided in Southern Florida, US, Sao
Paulo, Brazil or the state of Morelos, Mexico; (c) reported no previous diagnosis of
penile or anal cancer; (d) reported no prior diagnosis of genital or anal warts; (e) had not
participated in an HPV vaccine clinical trial; (f) reported no prior diagnosis of HIV or
AIDS; (g) were not currently being treated for an STI; (h) had not been imprisoned,
homeless or in drug treatment in the previous 6 months; and (i) were willing to complete
10 scheduled visits every six months over four years.
In the United States, men were recruited from a large university and the general
population in Tampa, FL via flyers, brochures and advertisements in local and university
newspapers. In Brazil, men were recruited from the general population of the
metropolitan area of São Paulo through several advertisements and from a large
urogenital care clinic. Participants in Brazil also included the partners of healthy women
who had participated in an HPV natural history study in Sao Paulo. In Cuernavaca,
Mexico, men were recruited through a state health plan, from local factories, and from
the military. All participants provided written informed consent and study protocols were
approved by Institutional Review Boards at each study site. A more detailed description
of the study design and population has been reported previously [3, 4, 35]. The present
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study includes 2,487 men who enrolled in the HIM Study before January 1, 2009, did not
have GW detected at enrollment, and completed at least one 6-month follow-up visit.
Genital wart identification
GW were identified by visual inspection of the external genitalia by a trained
clinician at each clinic visit. All GW were sampled with a saline pre-wetted Dacron swab
for the presence of HPV DNA. If multiple GW were detected, a separate specimen was
obtained from each lesion. Specimens were also obtained from healthy genital skin on
the coronal sulcus/glans penis, penile shaft, and scrotum for HPV DNA testing. GW
were sampled before healthy genital skin to avoid inter-specimen contamination.
Lesions that appeared to be related to Herpes Simplex Virus or a benign condition such
as skin tags or cysts were not sampled for HPV DNA.
HPV DNA testing
DNA was extracted from samples using the QIAamp Mini kit following the
manufacturer’s instructions (Qiagen, Valencia, CA). The polymerase chain reaction
(PCR) consensus primer system PGMY 09/11 was used to amplify a fragment of the
HPV L1 gene. Every PCR plate included a negative (H2O) and a positive (CaSki cell
DNA) control to test for possible contamination. The Linear Array HPV Genotyping Test
(Roche Diagnostics, Indianapolis, IN) was used to test for the presence of 37 HPV types,
including 13 oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) and
24 non-oncogenic types (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67–73, 81–84, IS39,
and CP6108). A sample was considered HPV positive if HPV DNA was detected by
PCR or it tested positive for at least one of the 37 HPV genotypes. Samples that
amplified HPV DNA by PCR but did not test positive for a specific HPV genotype were
considered unclassified infections. Beta-globin was detected in 93% (112/120) of GW
samples. The eight men with β-globin negative GW samples were excluded from all
analyses.
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Statistical analysis
GW incidence rates were calculated by dividing the number of incident cases by
the number of person-months of follow-up. Person-months were measured as the
number of months from the date of enrollment until the date the incident GW was
detected, or until the date of the last clinic visit for men who did not develop GW.
Incidence rates were calculated for individual HPV types and groups of HPV types (nononcogenic or oncogenic HPV types) detected on the surface of the GW. The 95%
confidence intervals (CIs) for incidence rates were calculated based on the Poisson
distribution [36]. All incidence rates were reported per 1,000 person-years.
The Kaplan-Meier method was used to estimate the 12 and 24 month cumulative
incidence of GW and the corresponding 95% CIs overall, by age group, and among men
with type specific incident HPV infections. Incident HPV infections were infections
detected at a follow-up visit after a man tested negative for the same HPV type at
enrollment. Men who did not develop GW were censored at the date of their last study
visit. The log-rank test was used to test for differences in risk of GW by age group (1830 years; 31-44 years; and 45-70 years) and by type of incident HPV infection (HPV
6/11 only; HPV 6/11 and other types; and HPV types other than 6/11). Among the 112
men who developed GW, the median time from type specific incident HPV infections to
GW detection was calculated as time in months from the date an incident HPV infection
was detected until the date the GW was detected.
Role of the funding source
Study sponsors had no role in the study design, data collection or analysis. The
corresponding author had full access to all data in the study and had final responsibility
for the decision to submit for publication.
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RESULTS
Study participants were followed for a median of 17.9 months (range, 4.5-46.9;
25th – 75th percentiles, 7.0-29.6), with112 incident cases of GW detected during followup. The mean age of participants was 32.6 years (standard deviation (SD), 11.4; range,
18-70), with 49% of men ages 18 to 30. Forty-five percent of men self-reported White
race and 45.2% self-identified as Hispanic. At baseline, 64.8% of men tested positive for
HPV DNA on the normal genital skin and 5.0% tested positive for HPV types 6 or 11
(data not shown).
Table 1 presents GW incidence rates and the distribution of HPV type groups
(oncogenic versus non-oncogenic) detected on the surface of GW. The overall
incidence rate for a newly acquired GW was 2.35 per 1,000 person-years and HPV DNA
was detected in 80.4% of GW. Forty-two percent of GW had non-oncogenic HPV types
only and HPV 6 and/or 11 was detected in 53.6% of the 112 incident GW and 66.7% of
the 90 GW that tested positive for HPV DNA. Five percent of GW tested positive for
oncogenic HPV types only and HPV 16/18 was detected in 12.5% of GW. Almost half of
GW tested positive for multiple types of HPV (45.5%) and 27.7% of GW tested positive
for a mix of oncogenic and non-oncogenic HPV types. Unclassified infections that tested
positive for HPV DNA by PCR but did not hybridize a specific HPV type occurred in 5.4%
of GW.
Table 2 presents HPV type specific incidence rates and the proportion of GW
that tested positive for specific HPV types. Non-oncogenic types HPV 6 (43.8%) and
HPV 11 (10.7%) were the most common types detected and had the highest incidence
rates (1.03 per 1,000 person-years and 0.25 per 1,000 person years, respectively). All
other HPV types were found in ≤10% of GW and had incidence rates of <1.0 per 1,000
person-years. Other common non-oncogenic HPV types detected were 62 (9.8%; 0.23
per 1,000 person-years) and 84 (8.9%; 0.21 per 1,000 person-years). The most
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common oncogenic HPV types detected were 16 (9.8%; 0.21 per 1,000 person-years)
and 52 (6.2%; 0.15 per 1,000 person-years). 58.9% of men who developed GW had an
HPV infection at a study visit prior to GW development with one or more of the same
HPV types detected on the surface of the GW. 65.3% of men with GW positive for HPV
6 and 58.3% of men with GW positive for HPV 11 had a preceding HPV infection with
types 6 and 11, respectively (data not shown).
The cumulative risk of developing GW was 1.7% (95% CI: 1.2-2.3) at 12 months
and 5.2% (95% CI: 4.1-6.4) at 24 months and the median time until detection of any GW
regardless of HPV status was 17.1 months (95% CI: 12.4-19.3 months) (Table 3).
Among men with an incident HPV infection with any type, cumulative incidence of GW
was 2.4% (95% CI: 1.6-3.3) at 12 months and 6.8% (95% CI: 5.0-8.6) at 24 months.
Though not statistically significant, cumulative incidence at 12 months was higher among
men with incident HPV infections with non-oncogenic types only (4.1%; 95% CI: 2.2-6.0)
compared to men with incident infections with oncogenic types only (1.8%; 95% CI: 0.03.5), or a mix of oncogenic and non-oncogenic types (1.5%; 95% CI: 0.5-2.4) (p=0.39).
Men with an incident HPV 6/11 infection had the highest probability of developing GW
(Figure 1). Twelve months after an incident HPV infection, 8.9% (95% CI: 0.0-18.1) of
men with HPV 6/11 only, 5.2% (95% CI: 1.8-8.5) of men with HPV 6/11 and other types,
and 2.5% (95% CI: 1.5-3.4) of men with HPV types other than 6/11 developed GW. The
probability of developing GW over 24-months was significantly higher among men with
an HPV infection that included HPV types 6/11 (14.6%; 95% CI: 7.5-21.1) than men with
an HPV infection not positive for types 6/11 (5.5%; 95% CI: 3.8-7.3) (p<0.0001) (Figure
1, Table 3). Time to GW detection was also shorter among men with an HPV infection
with type 6/11 only (6.2 months, 95% CI: 5.6-24.2), and among men with an HPV
infection with 6/11 and other HPV types (13.3 months; 95% CI: 6.3-19.6) than among
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men with an HPV infection with HPV types other than 6/11 (18.2 months; 95% CI: 12.423.6).
Incidence of GW significantly varied across age groups (p-value <0.0001) (Figure
2). Although the 24 month cumulative incidence of GW was highest in younger men
(7.4%; 95% CI: 5.4-9.4), mid adult (3.1%; 95% CI: 1.6-4.6) and older men (3.3%; 95%
CI: 0.9-5.6) remained at risk for GW and the shortest time to GW detection was
observed among men ages 45-70 (Table 4). There were no significant differences in GW
incidence across countries within each age group (data not shown).

DISCUSSION
In this multinational cohort of men ages 18-70 we estimated GW incidence, time
from HPV infection to GW detection, and described the distribution of HPV types
detected on the surface of incident GW. Men with incident HPV 6/11 infections had the
highest incidence of GW and shortest time from HPV infection to GW detection. HPV 6
(43.8%) and 11 (10.7%) were the most common types detected on GW, but there was
also a high prevalence of oncogenic types including HPV 16 (9.8%).
The incidence rate of GW among all men in our study was 2.35 per 1,000
person-years, with the highest incidence of 3.43 per 1,000 person-years observed
among men ages 18-30. Our findings are similar to incidence estimates from studies
using private health insurance claims that reported GW incidence rates of 1.70 [16], 1.62
[17], and 1.10 [15] per 1,000 person-years. Those studies also observed the highest
GW incidence among younger men. Two studies observed peak GW incidence among
men ages 25-29 (5.01 per 1,000 person-years [15] and 2.7 per 1,000 person-years [16]),
and one study observed the highest incidence among men ages 20-29 (3.1 per 1,000
person-years [17]). Higher GW incidence rates have been observed among individuals
in the placebo arms of HPV vaccine clinical trials: 8.7 per 1,000 person-years among
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females ages 15-26 [24] and 15.8 per 1,000 person-years among males ages 16-26
[32]. An enrollment criterion for the clinical trials was having four or fewer lifetime sexual
partners. The median number of lifetime sexual partners in the current study was six,
thus the lower GW incidence observed in the current study versus the clinical trials is
unexpected. One possible explanation is that young individuals just beginning to be
sexually active, and therefore exposed to HPV for the first time, have not developed the
immune response to clear an HPV infection and therefore are at higher risk of
developing GW. Time to clearance of an HPV infection is significantly longer in younger
men [3], who may consequently have a greater likelihood of developing a lesion.
Approximately 15% of men in the current study developed GW within 24 months
of an incident HPV 6/11 infection. This is lower than a cohort of university students in
which 58% of males [18] and approximately 60% of females [23] developed GW within
24 months of an incident HPV 6/11 infection. The age distribution of participants in each
study may partially account for the difference. The student cohort only included
individuals 18-21 while our study included men ages 18-70. However, the 24 month
cumulative incidence of GW after an incident HPV 6/11 infection was only 22.5% among
men ages 18-21 in our study. Differences in time intervals between clinic visits may also
contribute to our lower observed GW incidence. Men in our study had a slightly longer
time of six months between visits compared to the cohort of students who were
examined every four months. Given that the median time to clearance of GW was 5.9
months in the female students [23], it is possible there were men in our study who
developed and cleared an incident GW between the 6-month clinic visits.
Among men in our study with an incident HPV 6/11 infection, the median time to
GW detection was 12.2 months, similar to the median time of 11.0 months reported
among male university students with an incident HPV 6/11 infection [18]. Women
appear to have a shorter time from HPV 6/11 infections to GW detection; the placebo

13

arm of a vaccine trial in women reported median times of 5.0 months [24] and the study
of female university students reported a median time of 2.9 months [23]. It is not known
why GW develop more slowly in men, but this observation is consistent with findings of
peak GW incidence occurring at a slightly older age in men than in women [15, 16].
The prevalence of HPV 6/11 in GW in our study was 54%. Previous studies
reported the HPV 6/11 prevalence in GW to be 86% among young women in the
placebo arm of an HPV vaccine trial [24], 89% in men from Hong Kong [26], 90% among
French men ages 18-72 [27], and greater than 95% in two small US studies that
included fewer than 50 men [28, 33]. The lower than expected prevalence of HPV 6/11
observed in GW in the current study may be the result of misclassification. Preliminary
biopsy data collected from a small sample of lesions identified in the HIM Study found
39% of lesions diagnosed as GW by visual inspection were not true GW by pathology.
The high rate of false positives suggests that non-condyloma skin conditions were
classified as condyloma based on visual inspection and therefore were not positive for
HPV 6/11. We also observed a high proportion of oncogenic HPV types in GW (33.1%),
with HPV 16 (9.8%) being the most common type detected after HPV 6 (43.8%) and
HPV 11 (10.7%). This finding is consistent with other studies that also reported a high
prevalence of oncogenic HPV types in GW [24, 26, 27, 33].
The major limitation of this study was reliance on visual inspection to identify
GW. Without pathological confirmation that lesions were GW, it is possible that nonHPV related skin conditions were incorrectly classified as GW. The lower than expected
prevalence of HPV 6/11 and the slightly higher incidence rates of GW compared to
previous studies [15-17] suggests some misclassification is present. The generalizability
of our findings may also be limited, since men who agree to participate in a four-year
study are likely not representative of the underlying population at each study site.
However, our findings are likely more generalizable to a broader population than findings
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from clinical trials, which have a more select group of individuals due to more stringent
selection criteria. Also, HPV detection in the current study was based on samples
obtained by sampling the surface of the GW, and therefore, the types detected may not
represent the types present in the lesions themselves. However, a small sample of
histologically confirmed condyloma from the HIM Study found swabbing the surface of
the lesion was a highly sensitive and specific method for detecting the HPV types
present within the condyloma tissue [37].
The major strength of the current study was the longitudinal study design and
long duration of follow-up. Repeated measures of HPV status over follow-up enabled
the examination of how time to GW development differed after incident HPV infections
with specific types. We also included men from a broader age range than most previous
studies, which allowed us to examine how incidence of GW differed with age.
This study is one of the first to examine progression from HPV infection to GW
including men from across the lifespan. Though younger men had the highest incidence
of GW mid-adult and older men still remained at risk of acquiring GW. HPV 6/11
appears to play an important role in GW development with the highest incidence and
shortest time to GW development observed among men with incident HPV 6/11
infections. Future studies should confirm these incidence estimates among histologically
confirmed GW.
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Table 2.1. Genital wart incidence by grouped HPV types detected on the
surface of the lesion.
Incidence per 1,000
person-years
(95% Confidence
a
Interval)
HPV type detected on surface of GW
n (%)
Incidence of GW regardless of HPV type
detected on the lesion

112 (100.0)

2.35 (1.94-2.83)

Positive for HPV

90 (80.4)

1.89 (1.52-2.33)

Non-oncogenic HPV types only
HPV 6/11
Oncogenic HPV types only
HPV 16/18

47 (42.0)
60 (53.6)
6 (5.4)
14 (12.5)

0.99 (0.73-1.31)
1.26 (0.96-1.62)
0.13 (0.05-0.27)
0.29 (0.16-0.49)

Both non-oncogenic and oncogenic HPV types
Positive for multiple HPV types

31 (27.7)
51 (45.5)

0.65 (0.44-0.93)
1.05 (0.78-1.39)

6 (5.4)

0.13 (0.05-0.27)

b

Unclassified infections

c

a

Denominator is the 112 men who developed incident GW.
Includes unclassified HPV infections.
b
Infections that tested positive for HPV DNA by PCR but did not test positive for any
of the 37 HPV types.
b
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Table 2.2. Genital wart incidence by individual HPV types detected on the
surface of the lesion.
No. men who developed
Incidence of GW per
GW with HPV type
1,000 person-years
a,b
n (%)
(95% Confidence Interval)
Non-oncogenic HPV
6
49 (43.8)
1.03 (0.76-1.36)
11
12 (10.7)
0.25 (0.13-0.44)
26
0 (0.0)
40
7 (6.2)
0.15 (0.06-0.30)
42
6 (5.4)
0.13 (0.05-0.27)
53
8 (7.1)
0.17 (0.07-0.33)
54
5 (4.5)
0.11 (0.03-0.25)
55
7 (6.2)
0.15 (0.06-0.30)
61
2 (1.8)
0.04 (0.01-0.15)
62
11 (9.8)
0.23 (0.12-0.41)
64
0 (0.0)
67
1 (0.9)
0.02 (0.00-0.12)
68
3 (2.7)
0.06 (0.01-0.18)
69
0 (0.0)
70
0 (0.0)
71
2 (1.8)
0.04 (0.01-0.15)
72
2 (1.8)
0.04 (0.01-0.15)
73
1 (0.9)
0.02 (0.00-0.12)
81
1 (0.9)
0.02 (0.00-0.12)
82
1 (0.9)
0.02 (0.00-0.12)
83
2 (1.8)
0.04 (0.01-0.15)
84
10 (8.9)
0.21 (0.10-0.39)
IS39
0 (0.0)
CP6108
7 (6.2)
0.15 (0.06-0.3)
Oncogenic HPV
16
11 (9.8)
0.21 (0.10-0.39)
18
4 (3.6)
0.08 (0.02-0.22)
31
1 (0.9)
0.02 (0.00-0.12)
33
0 (0.0)
35
0 (0.0)
39
5 (4.5)
0.11 (0.03-0.25)
45
1 (0.9)
0.02 (0.00-0.12)
51
6 (5.4)
0.13 (0.05-0.27)
52
7 (6.2)
0.15 (0.06-0.30)
56
1 (0.9)
0.02 (0.00-0.12)
58
4 (3.6)
0.08 (0.02-0.22)
59
5 (4.5)
0.11 (0.03-0.25)
66
6 (5.4)
0.13 (0.05-0.27)
a
Denominator is the 112 men who developed incident GW.
b
Percentages do not sum to 100 due to men having multiple HPV types and being
included in multiple HPV categories..
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Table 2.3. Cumulative incidence of genital warts at 12 and 24 months and median time from incident HPV infection
to genital wart detection.
Median time in months
a
12 month cumulative
24 month cumulative
from HPV infection to
incidence, %
incidence, %
GW detection
a
Incident HPV infection genotype
(95% CI)
(95% CI)
(95% CI)
b
b
c
Incidence of GW regardless of HPV status
1.7 (1.2-2.3)
5.2 (4.1-6.4)
17.1 (12.4-19.3)
Negative for HPV
1.1 (0.1-2.2)
1.8 (0.1-3.5)
N/A
Positive for HPV
2.4 (1.6-3.3)
6.8 (5.0.-8.6)
12.6 (12.1-18.4)
Non-oncogenic HPV types only
4.1 (2.2-6.0)
6.7 (3.9-9.4)
7.6 (6.2-12.2)
Oncogenic HPV types only
1.8 (0.0-3.5)
5.5 (0.9-9.9)
19.4 (6.2-23.5)
Both non-oncogenic and oncogenic HPV types
1.5 (0.5-2.4)
6.8 (4.3-9.3)
18.8 (12.7-23.9)
d
IHPV 6/11
5.8 (2.6-9.0)
14.6 (7.5-21.1)
12.2 (6.2-18.9)
HPV 6/11 only
8.9 (0.0-18.1)
13.7 (0.0-25.8)
6.2 (5.6-24.2)
HPV 6/11 and other HPV types
5.2 (1.8-8.5)
14.5 (6.7-21.7)
13.3 (6.3-19.6)
HPV types other than 6/11
2.5 (1.5-3.4)
5.5 (3.8-7.3)
18.2 (12.4-23.6)
Note: CI-confidence interval.
a
Incident HPV infection that occurred before development of GW.
b
Cumulative incidence of GW among all 2,487 men regardless of HPV infection status.
c
Median time from enrollment visit to GW detection.
d
Includes incident HPV infections with 6/11 only and infections with 6/11 and other HPV types.
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Table 2.4. Cumulative incidence of genital warts at 12 and 24 months and median time to genital wart
detection by age groups.
Median time in months from
Incidence per 1,000 12 month cumulative 24 month cumulative
incident HPV infection to GW
incidence-%
incidence-%
person-years
Age group
detection
(95% CI)
(95% CI)
(95% CI)
(years)
(95% CI)
18-30
3.43 (2.72-4.27)
2.3 (1.4-3.2)
7.4 (5.4-9.4)
17.2 (12.3-19.5)
31-44
1.37 (0.89-2.02)
1.0 (0.3-1.7)
3.1 (1.6-4.6)
18.9 (11.9-24.2)
45-70
1.27 (0.55-2.51)
1.7 (0.2-3.2)
3.3 (0.9-5.6)
7.6 (5.8-13.6)
Note: CI-confidence interval.
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Figure 2.1. Cumulative probability of genital warts among men with
incident HPV infections with HPV 6/11 only, HPV6/11 and other HPV types,
and only HPV types other than 6/11.
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Figure 2.2. Cumulative probability of genital warts by age groups.
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CHAPTER 3: SECOND MANUSCRIPT: RISK FACTORS FOR CONDYLOMA IN A
MULTINATIONAL COHORT OF MEN: THE HIM STUDY

ABSTRACT
Background: Little is known about the sociodemographic and sexual behavior factors
associated with incident genital warts (GW) in men.
Methods: A cohort of 2,487 men from the US, Brazil and Mexico were followed every
6-months for a median of 17.9 months. At each study visit men completed a
questionnaire to obtain information on sexual behavior and a trained clinician identified
GW by visual inspection and sampled for the presence of human papillomavirus (HPV).
Cox proportional hazards models were used to examine factors independently
associated with incident GW.
Results: Factors associated with GW were incident HPV 6/11 infection (hazard ratio
(HR)=12.42; 95% confidence interval (CI): 3.78-40.77), younger age (HR=0.43; 95% CI:
0.26-0.77; 45-70 vs. 18-30 years), high lifetime number of female partners (HR=5.69;
95% CI: 1.80-17.97); ≥21 vs. 0), and sexual behaviors in the previous three months
including infrequent condom use (HR=2.44; 95% CI: 1.16-5.14; <half the time vs.
always), number of male sexual partners (HR=4.53; 95% CI: 1.68-12.20; ≥3 vs. none),
frequent vaginal intercourse (HR=4.14; 95% CI: 1.32-13.01); ≥21 times vs. none), having
a partner with GW (HR=2.38; 95% CI: 1.01-5.61), and being diagnosed with a sexually
transmitted infection (HR=1.99; 95% CI: 1.17-3.39).
Conclusion: HPV 6/11 and recent sexual behavior were most strongly associated with
incident GW in men.
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NTRODUCTION
Genital warts (GW) are one of the most prevalent sexually transmitted infections
(STI) in the United States (US), and the incidence of GW has been increasing in the last
decade [17]. Approximately 90% of GW are associated with human papillomavirus
(HPV), particularly non-oncogenic HPV types 6 and 11 [27]. Though GW are not
associated with mortality, they are a source of emotional distress and reduced quality of
life [9, 10, 38]. GW have a high transmission rate between sexual partners [11], and
treatment of GW is often ineffective with about one-fourth of cases recurring within 3
months of treatment [12]. Identifying factors associated with GW can contribute to
prevention efforts that focus on behavioral modification.
Only a few studies have examined the factors associated with the development
of GW in men [19-22], and most of these studies were among highly selective
populations including STI clinic attendees [20, 21] and men who have sex with men [22].
Similarly, many studies examining risk factors for GW in women have also been in select
populations such as university students [23], STI clinic attendees [20], and young
women in the placebo arm of an HPV vaccine trial [24]. The purpose of this study was
to identify sociodemographic and sexual behavioral factors associated with the incidence
of GW in a cohort of men ages 18-70 residing in the US, Brazil, and Mexico.

METHODS
Study population
The HPV in Men (HIM) Study is a multinational prospective study of men ages
18-70 that examines the natural history of HPV infection in men. Participants were
enrolled between July 2005 and September 2009 and met the following inclusion criteria:
(a) were ages 18-70 years old; (b) resided in Southwest Florida, Sao Paulo, Brazil or the
state of Morelos Mexico;
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(c) reported no previous diagnosis of penile or anal cancer; c no prior diagnosis of
genital or anal warts; (e) had not participated in an HPV vaccine clinical trial; (f) reported
no prior diagnosis of HIV or AIDS; (g) were not currently being treated for an STI; (h) had
not been imprisoned, homeless or in drug treatment in the previous six months; and (i)
were willing to complete 10 scheduled visits every six months over four years.
The current analysis included the first 2,487 men enrolled in the HIM study
through January 1, 2009 who did not have GW detected at enrollment and completed at
least one 6-month follow-up visit. All participants provided written informed consent and
study protocols were approved by Institutional Review Boards at each study site.
Study design
Men completed a pre-enrollment run-in visit followed by an enrollment visit
approximately two weeks later. After enrollment, men returned approximately every six
months for eight additional follow-up visits. At each study visit participants completed an
extensive risk factor questionnaire in their native language (English, Spanish, or
Portuguese), administered using Computer-Assisted Self-Interviewing. The survey
obtained information about sociodemographic factors and lifetime and recent sexual
behavior.
At each clinic visit a trained clinician examined men for genital lesions. GW were
lesions with a wart-like architecture that did not appear to be related to Herpes Simplex
virus or a benign condition such as pearly penile papules, skin tags, cysts, or Fordyce
spots. Saline-prewetted Dacron swabs were used to obtain samples of healthy penile
epithelium from the coronal sulcus/glans penis, penile shaft, and scrotum. The three
samples were combined for HPV DNA testing and genotyping. A full description of study
procedures has been published previously [3, 4, 35].
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HPV DNA testing
Polymerase chain reaction (PCR) was used to test for HPV DNA. Following the
instructions of the manufacturer (Qiagen, Valencia, CA), the QIAamp Mini kit was used
to extract DNA from the skin swabs. A fragment of the HPV L1 gene was amplified
using the PCR consensus primer system PGMY 09/11. The Linear Array HPV
Genotyping Test (Roche Diagnostics, Indianapolis, IN) was used to test for 37 HPV
types, including 13 oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and
66) and 24 non-oncogenic types (6, 11, 26, 40, 42, 53, 54, 55, 61, 62, 64, 67–73, 81–84,
IS39, and CP6108). HPV genotyping was conducted on all samples, regardless of HPV
PCR result. A sample was classified as HPV positive if HPV DNA was detected by PCR
or the sample tested positive for at least one of the 37 HPV genotypes tested for.
Statistical analysis
The Pearson’s chi-squared test for categorical variables and the t-test for
continuous variables were used to compare the baseline distribution of
sociodemographic characteristics and sexual behavior factors between men with
incident GW and men who did not develop GW. Cox proportional hazard models were
used to calculate hazard ratios (HRs) and 95% confidence intervals (CIs) for the
association between incident and prevalent HPV infection and risk of GW. An individual
had an incident HPV infection for a specific HPV type if he tested negative for that type
at enrollment and later tested positive for the same type at a follow-up visit. Prevalent
HPV infections were infections present at enrollment. The reference group for all
models assessing the association between HPV infection and GW was men who tested
negative for HPV at all study visits. Person-time was calculated as the months from the
enrollment date until the date of the visit at which a GW was detected or until the last
follow-up visit for men who did not develop GW.
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Cox proportional hazard models were also used to examine crude and
multivariable associations between sociodemographic and sexual behavior factors and
the risk of developing GW. The backward selection method, with a significance
threshold of 0.05, was used to determine the factors included in the final multivariable
model. Variables initially included were: race, ethnicity, marital status, education,
cigarette smoking status, circumcision status, age at first intercourse with a female,
lifetime and recent number of female and male sexual partners, sexual orientation,
condom use, frequency of vaginal intercourse, having a steady female partner, ever
being diagnosed with an STI, ever having a partner with an STI, ever having a partner
with GW, and incident HPV 6/11 infection. Country of residence (US; Brazil; Mexico) and
age (18-30 years; 31-44 years; 45-70 years) were study design factors and therefore
included in all multivariable models. Covariates that could change over the follow-up
period, (e.g., recent number of female partners), were treated as time-dependent
variables. The final multivariable model was run including among all men in the cohort
(n=2487) and then restricted to men who had an incident HPV infection of any type
during follow-up (n=1498). All p-values were 2-sided and considered significant if below
0.05. Statistical analyses were conducted using SAS version 9.1.

RESULTS
Men were followed for a median of 17.9 months (range, 4.5-46.9; 25th – 75th
percentiles, 7.0-29.6), and 112 men developed GW. Table 1 compares the baseline
distribution of sociodemographic and sexual behavior factors between men who
developed GW and men who did not. Compared to men who did not develop GW, men
with incident GW were significantly younger, more likely to be White, current smokers,
circumcised, have a high number of lifetime female sexual partners, have more female
sexual partners in the previous three months, and not always use condoms.
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Table 2 presents the associations between types of HPV infections and risk of
subsequent GW. The strongest associations were observed for infections with nononcogenic HPV types 6/11. Compared to men who never tested positive for HPV, there
was a significant increased risk for GW among men with an incident HPV infection with
types 6/11 only (HR=12.42; 95% CI: 3.78-40.77) and among men with an incident
infection with HPV 6/11 and other types (HR=7.74; 95% CI: 3.10-19.31). Risk of GW
was also significantly higher among men with an incident infection with non-oncogenic
HPV types only (HR=3.63; 95% CI: 1.49-8.83) or a mix of non-oncogenic and oncogenic
types (HR=3.94; 95% CI: 1.68-9.27). There was no significant increased risk for GW
among men with incident infections with oncogenic HPV types only (HR=2.42; 95% CI:
0.56-6.86) or men with incident infections with HPV types other than 6/11 (HR=2.16;
95% CI: 0.93-5.02). Similar associations were observed for prevalent HPV infections at
enrollment, with the highest risk for GW among men with an HPV infection with types
6/11 only (HR=16.78; 95% CI: 5.97-47.19).
Table 3 presents the risk of GW for factors that remained in the final multivariable
model, while adjusting for HPV 6/11 infection, for the entire cohort (n=2,487) and
restricted to men with an incident HPV infections (n=1,498). For the entire cohort, the
factors independently associated with risk of GW, while adjusting for infection with HPV
6/11, were country, age, lifetime number of female sexual partners, recent condom use,
recent number of male anal sex partners, frequency of vaginal intercourse in the past
three months, ever having a partner with GW, and ever being diagnosed with an STI.
Compared to men residing in the US, the risk of GW was lower for men living in Brazil
(HR=0.33; 95% CI: 0.20-0.54) and Mexico (HR=0.45; 95% CI: 0.26-0.77). Risk of GW
decreased with age and was comparable among men ages 31-44 (HR=0.44; 95% CI:
0.27-0.71) and 45-70 (HR=0.43; 95% CI: 0.20-0.92) compared to men ages 18-30.
Compared to men who reported no female sexual partners in their lifetime, risk of GW

27

increased with an increasing number of female partners (p for trend: <0.0001). The
significant increase in risk however was only among men with six or more lifetime female
partners. Risk of GW was also significantly higher among men who refused to report
lifetime number of female partners. However, including these men in the model did not
bias results, as there were no major differences in risk estimates when the multivariable
model was run after excluding these 135 men (data not shown). Sexual behaviors in the
previous three months that were associated with an increased risk of GW were a high
number of male anal sex partners (HR=4.53; 95% CI: 1.68-12.20 for men who reported
three or more recent male partners compared to men with no recent male partners),
more frequent vaginal intercourse (HR=4.14; 95% CI: 1.31-13.01 for ≥21 times
compared to men who reported no vaginal intercourse in the recent past), and infrequent
condom use (HR=2.44; 95% CI: 1.16-5.14 for using condoms less than half the time vs.
always). Ever being diagnosed with an STI (HR=1.99; 95% CI: 1.17-3.39) and ever
having a partner with GW (HR=2.38; 95% CI: 1.01-5.61) also increased the risk of GW.
The multivariable model was also run restricted to men with an incident HPV
infection to examine which factors in addition to HPV were associated with incident GW
(Table 3). Factors that remained significantly associated with GW were country, age,
lifetime number of female partners, recent condom use, and being diagnosed with an
STI. Recent number of male anal sex partners, frequency of vaginal intercourse in the
previous three months, and having a partner with GW were not significantly associated
with risk of GW among men with an incident HPV infection.

DISCUSSION
In this cohort of men ages 18-70 from the US, Brazil, and Mexico, HPV 6/11
infections were most strongly associated with incidence of GW. Recent sexual
behaviors associated with incidence of GW were condom use, recent number of male

28

anal sex partners, frequency of vaginal intercourse, having a partner with GW, and
testing positive for an STI. This is the first study to use a prospective design to examine
sexual behaviors associated with GW, thus minimizing recall bias that may have
occurred in previous case-control studies. The current study also includes men largely
from the general community, making the results more generalizable than previous
studies which included men from more select populations.
In our cohort, men with incident HPV infections with only types 6/11 had the
highest risk of developing GW. Previous analyses of this cohort of men also found the
highest incidence of GW and shortest time from HPV infection to GW detection among
men with incident HPV 6/11 infections (data not shown). The strong association
between HPV 6/11 and GW has also been observed among females enrolled in the
placebo arm of an HPV vaccine trial [24]; women who tested positive for HPV 6/11 at
baseline were 29 times more likely to develop GW in the first year of follow-up compared
to women negative for HPV 6/11. The same study saw a significant increased risk for
GW among women who had HPV infections with oncogenic types only. We also saw
an increased risk of GW among men with HPV infections with oncogenic types only at
enrollment. It is likely that the men with oncogenic infections at enrollment acquired a
subsequent non-oncogenic HPV infection prior to GW development.
Consistent with the nature of a sexually transmitted disease, the risk of GW was
highest among men with a high lifetime number of female sexual partners or more
frequent vaginal intercourse. The association between a high lifetime number of female
partners and risk of GW was also observed in STI clinic attendees [20] and male
members of a health maintenance organization [19]. A higher number of sexual partners
and more frequent sexual intercourse increase a man’s chance of being exposed to
HPV. Having a high number of female partners [3, 35, 39, 40] and frequent sexual
intercourse [39] are both significantly associated with HPV infection in men. We also
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observed a significant increased risk for GW among men who refused to report their
lifetime number of female partners. These men likely had a high number of partners but
did not provide an answer because they were not sure of the exact number or they were
embarrassed to report a large number.
Always using condoms was protective against GW in our cohort. Frequent
condom use was also protective against GW in a study of STI clinic attendees [20], but
no association was observed in a study of male health maintenance organization
members [19]. Similarly, there have been inconsistent findings on the protective effect
of condom use against HPV infection in men [41]. Condoms provide a protective barrier
against the transmission of HPV by skin to skin contact; however, men can be infected
with HPV on areas not protected by a condom. We did not observe an increased risk for
GW among the men who reported never using condoms in the recent past. Frequent
condom use may be a marker for engaging in high risk sexual behavior such as having
multiple partners, while not using condoms may be a marker for low risk behavior such
as being in a monogamous relationship. The increased risk of GW among men
reporting no vaginal sex in the last three months was likely due to the fact that this
category included men who had one or more male anal sex partners in the recent past.
Men who had three or more male anal sex partners in the previous three months
had a significantly increased risk of GW compared to men with no recent male partners.
This observation is consistent with results from a male vaccine trial in which men who
had sex with men had an incidence rate of GW more than twice as high as men who
only had sex with women [32]. However, lifetime number of male sexual partners was
not associated with GW in our study. We also did not observe an increased risk for GW
among men with a high number of recent female partners, consistent with a study of STI
attendees that found no association between GW and the number of sexual partners in
the previous 12 months [21]. Having had a partner with GW significantly increased the
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risk for GW. This observation is consistent with the high transmission rate of GW
between partners [11] and a finding that men with a female partner with GW are more
likely to be HPV positive [42].
Though age is not associated with incidence of HPV infection in men [3], we
found the that risk of GW significantly decreased with age independent of sexual
behavioral factors including lifetime number of female partners. This age pattern has
consistently been observed in other studies examining risk factors for GW in men [19-22]
as well as GW incidence estimates based on data from US insurance claims [15-17].
Changes in immune response with increasing age may be related to the lower incidence
of GW in older men. Though the prevalence of HPV in men remains steady across the
lifespan, older men clear HPV infections faster than younger men [3] and increasing age
is associated with higher levels of antibodies against HPV types 6 and 11 [43]. More
rapid clearance and a stronger immune response may reduce the likelihood that an HPV
infection progresses to a lesion.
There was a significantly reduced risk of GW among men in Brazil and Mexico
compared to men in the US. The difference in risk across countries may be partially due
to residual confounding by age; country remained a significant factor when the final
multivariable model was run among men ages 18-30, but the association with country
did not remain significant in models restricted to men ages 31-44 or 45-70 (data not
shown).
There are limitations to the current study that should be considered when
interpreting the results. GW were identified by visual inspection, therefore
misclassification may exist if lesions we classified as GW were actually a non-HPV
related benign skin condition. However, misclassification of GW would likely be nondifferential with respect to sexual behavior and, therefore, result in underestimates of the
associations between GW and various risk factors. The generalizability of our findings is
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likely limited due to the self-selection of participants. Men who agree to participate in a
four year prospective study may not be representative of the underlying population from
each country. However, our results are likely more generalizable than studies that only
included men who have sex with men or men who were seeking treatment for an STI.
Strengths of our study included use of an extensive questionnaire to collect data
for a variety of potential risk factors and a prospective study design that allowed us to
obtain data on sexual behavior before men developed GW. Previous studies of risk
factors for GW in men were case-control studies that collected risk factor data after men
were diagnosed with GW, potentially leading to biased results if being diagnosed with
GW caused men to alter their sexual behavior (e.g., use condoms more frequently) or
affected how accurately they recalled their sexual habits. By collecting data on lifetime
and recent sexual behavior before men were diagnosed with GW, recall bias was
minimized.
In summary, the factors independently associated with an increased risk of GW
in this cohort of men ages 18-70 included incident HPV 6/11 infection, a high number of
lifetime female or recent male sexual partners, frequent vaginal intercourse, infrequent
condom use, having with a partner with GW and ever being diagnosed with an STI. The
strong association between recent sexual history and incident condyloma after
accounting for HPV infection suggests that prevention efforts targeting behavioral
modification may be effective at reducing condyloma incidence among men who are not
vaccinated.
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Table 3.1. Distribution of sociodemographic and sexual behavior characteristics of
cohort members at enrollment.
No Genital
Warts
Genital Warts
(N=112)
(N=2375)
a
n (%)
n (%)
p-value
Country
United States
61 (54.5)
657 (27.7)
<0.0001
Brazil
31 (27.7)
935 (39.4)
Mexico
20 (17.9)
783 (33.0)
Age
18-30
79 (70.5)
1142 (48.1)
<0.0001
31-44
25 (22.3)
903 (38.0)
45-70
8 (7.1)
330 (13.9)
Mean (SD)
28.5
32.8
<0.0001
Race
White
70 (62.5)
1046 (44.0)
<0.01
Black
16 (14.3)
385 (16.2)
Asian/Pacific Islander
0 (0.0)
59 (2.5)
American Indian
1 (0.9)
54 (2.3)
Mixed/Mestizo
24 (21.4)
802 (33.8)
Unknown/Refused
1 (0.9)
29 (1.2)
Current smoker
Yes
27 (24.1)
500 (21.1)
0.04
No
84 (75.0)
1873 (78.9)
Refused
1 (0.9)
2 (0.1)
Circumcision (clinician assessed)
Yes
65 (58.0)
774 (32.6)
<0.0001
No
47 (42.0)
1601 (67.4)
Sexual orientation at enrollment
Men who have sex with women only
98 (87.5)
1971 (83.0)
0.18
Men who have sex with women and men
6 (5.4)
129 (5.4)
Men who have sex with men only
5 (4.5)
113 (4.8)
Never had sex
2 (1.8)
157 (6.6)
Refused
1 (0.9)
5 (0.2)
Lifetime no. of female sexual partners
0
5 (4.5)
254 (10.7)
<0.01
1
6 (5.4)
205 (8.6)
2 to 5
20 (17.9)
654 (27.5)
6 to 10
28 (25.0)
463 (19.5)
11 to 20
21 (18.8)
353 (14.9)
≥21
24 (21.4)
319 (13.4)
Refused
8 (7.1)
127 (5.4)
Total no. of female partners in past 3 months
None
17 (15.2)
813 (34.2)
<0.0001
1
49 (43.8)
934 (39.3)
2
23 (20.5)
288 (12.1)
≥3
21 (18.8)
271 (11.4)
Refused
2 (1.8)
69 (2.9)
No. of new female partners in past 3 months
None
63 (56.3)
1506 (63.4)
0.08
1
29 (25.9)
523 (22.0)
2
9 (8.0)
124 (5.2)
≥3
9 (8.0)
106 (4.5)
Refused
2 (1.8)
116 (4.9)
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Table 3.1. Distribution of sociodemographic and sexual behavior characteristics of
cohort members at enrollment (Contd.).
No Genital
Warts
Genital Warts
(N=112)
(N=2375)
a
n (%)
n (%)
p-value
Condom use during vaginal intercourse in
past 3 months
Always
27 (24.1)
436 (18.4)
0.03
At least half the time
30 (24.8)
424 (17.9)
<Half the time
16 (14.3)
279 (11.8)
Never
26 (23.2)
732 (30.8)
No vaginal sex in the past 3 months
13 (11.6)
475 (20.0)
Refused
0 (0.0)
29 (1.2)
No. of times of vaginal intercourse in past 3
months
None
19 (17.0)
696 (29.3)
0.07
1 to 5
22 (19.6)
342 (14.4)
6 to 20
30 (26.8)
566 (23.8)
≥21
35 (31.3)
647 (27.2)
Refused
6 (5.4)
124 (5.2)
Lifetime no. of male anal sex partners
None
97 (86.6)
2013 (84.8)
0.80
1
3 (2.7)
99 (4.2)
2
3 (2.7)
61 (2.6)
≥3
7 (6.3)
180 (7.6)
Refused
2 (1.8)
22 (0.9)
No. of male anal sex partners in past 3
months
None
105 (93.8)
2218 (93.4)
0.70
1
3 (2.7)
54 (2.3)
2
0 (0.0)
25 (1.1)
≥3
4 (3.6)
64 (2.7)
Refused
0 (0.0)
14 (0.6)
Ever had a partner with an STI
Yes
27 (24.1)
372 (15.7)
0.12
No
48 (42.9)
1181 (49.7)
Don't know
37 (33..0)
821 (34.6)
Refused
0 (0.0)
1 (0.1)
Ever had a partner with genital warts
Yes
9 (8.0)
120 (5.1)
0.34
No
70 (62.5)
1582 (66.6)
Don't know
33 (29.5)
673 (28.3)
Refused
0 (0.0)
0 (0.0)
Ever been diagnosed with an STI by a doctor
Yes
22 (19.6)
387 (16.3)
0.08
No
86 (76.8)
1923 (81.0)
Don't know
3 (2.7)
63 (2.7)
Refused
1 (0.9)
2 (0.1)
a
Differences between groups was tested with the chi-squared test for categorical variables
and t-test for continuous variables.
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Table 3.2. Independent association between HPV infection and risk of genital warts.
No
Genital Warts Genital Warts
Hazard Ratio
(n=112)
(n=2375)
(95% Confidence
n (%)
n (%)
Interval)
a

No HPV infection
INCIDENT HPV INFECTIONS
Any HPV type
Non-Oncogenic HPV types only
Oncogenic HPV types only
Both non-oncogenic and oncogenic types
b
HPV 6/11
HPV 6/11 only
HPV 6/11 and other HPV types
HPV infection without types 6/11

6 (5.4)

410 (17.3)

1.00 (ref)

80 (71.4)
27 (24.0)
9 (8.0)
44 (39.3)
25 (22.3)
5 (4.5)
20 (17.9)
55 (49.1)

1418 (59.7)
527 (22.2)
290 (12.2)
601 (25.3)
199 (8.4)
31 (1.3)
168 (7.1)
1219 (51.3)

3.80 (1.65-8.73)
3.63 (1.49-8.83)
2.42 (0.56-6.86)
3.94 (1.68-9.27)
7.95 (3.25-19.43)
12.42 (3.78-40.77)
7.74 (3.10-19.31)
2.16 (0.93-5.02)

PREVALENT HPV INFECTIONS
Any HPV type
Non-Oncogenic HPV types only
Oncogenic HPV types only
Both non-oncogenic and oncogenic types
b
HPV 6/11
HPV 6/11 only
HPV 6/11 and other HPV types
HPV infection without types 6/11

93 (83.0)
21 (18.8)
24 (21.4)
42 (37.5)
24 (21.4)
9 (8.0)
15 (13.4)
69 (61.6)

1518 (63.9)
491 (20.7)
279 (11.8)
386 (16.3)
101 (4.3)
20 (0.8)
81 (3.4)
1417 (59.7)

3.31 (1.45-7.56)
2.34 (0.95-5.81)
4.44 (1.81-10.88)
6.29 (2.67-14.80)
11.12 (4.54-27.21)
16.78 (5.97, 47.19)
9.55 (3.70-24.63)
2.65 (1.15-6.11)

a

Reference group for all models.

b

Includes HPV infections with 6/11 only and infections with 6/11 and other HPV types.
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Table3.3. Multivariable associations for sociodemographic and sexual behavior
factors with genital wart incidence after accounting for HPV 6/11 infection.
Multivariable
Entire cohort
(N=2487)
c
HR (95% CI)

Multivariable
Men with
incident HPV
(N=1498)
c
HR (95% CI)

1.00 (ref)
0.33 (0.20-0.54)
0.45 (0.26-0.77)

1.00 (ref)
0.32 (0.18-0.56)
0.26 (0.12-0.55)

1.00 (ref)
0.44 (0.27-0.71)
0.43 (0.20-0.92)

1.00 (ref)
0.51 (0.29-0.89)
0.28 (0.10-0.82)

1.00 (ref)
1.84 (0.51-6.56)
2.26 (0.74-6.88)
4.30 (1.42-12.98)
4.37 (1.41-13.53)
5.69 (1.80-17.97)
5.99 (1.73-20.72)
<0.0001

1.00 (ref)
2.18 (0.45-10.66)
2.94 (0.72-11.95)
4.71 (1.19-18.65)
6.00 (1.51-23.80)
7.76 (1.91-31.49)
5.19 (1.06-25.27)
<0.001

1.00 (ref)
2.34 (1.17-4.69)
2.44 (1.16-5.14)
1.31 (0.63-2.71)

1.00 (ref)
2.81 (1.13-6.96)
2.69 (1.03-7.01)
1.65 (0.64-4.24)

4.25 (1.17-15.48)
0.88 (0.05-16.38)

4.70 (0.97-22.92)
1.04 (0.02-58.41)

1.00 (ref)
1.10 (0.26-4.70)
3.17 (0.71-14.07)
4.53 (1.68-12.20)
2.75 (0.71-10.75)

1.00 (ref)
1.25 (0.29-5.430)
1.89 (0.24-14.75)
2.60 (0.68-9.95)
3.40 (0.79-14.59)

1.00 (ref)
2.13 (0.58-7.77)
2.94 (0.90-9.57)
4.14 (1.32-13.01)
2.63 (0.87-7.96)

1.00 (ref)
1.57 (0.33-7.38)
1.70 (0.42-6.97)
2.99 (0.77-11.52)
2.10 (0.54-8.16)

1.00 (ref)
2.38 (1.01-5.61)
2.34 (1.51-3.64)
1.46 (0.08-26.46)

1.00 (ref)
2.40 (0.84-6.87)
2.50 (1.49-4.19)
1.04 (0.02-56.5)

Crude
HR (95% CI)

Country
United States
1.00 (ref)
Brazil
0.44 (0.29-0.69)
Mexico
0.39 (0.24-0.65)
Age
18-30
1.00 (ref)
31-44
0.40 (0.25-0.62)
45-70
0.38 (0.18-0.79)
Lifetime no. female sexual
partners
0
1.00 (ref)
1
1.63 (0.50-5.34)
2 to 5
1.72 (0.65-4.58)
6 to 10
3.45 (1.33-8.94)
11 to 20
3.29 (1.24-8.73)
≥21
4.08 (1.55-10.70)
Refused
3.36 (1.10-10.28)
p for trend
<0.0001
Condom use during vaginal
intercourse in the past three
a
months
Always
1.00 (ref)
At least half the time
3.26 (1.66-6.44)
Less than half the time
3.00 (1.45-6.20)
Never
1.26 (0.62-2.57)
No vaginal sex in the
b
past three months
1.34 (0.63-2.87)
Refused
1.97 (0.44-8.89)
No. male anal sex partners
a
in past three months
None
1.00 (ref)
1
1.26 (0.75-2.12)
2
1.88 (0.93-3.79)
≥3
2.75 (1.47-5.13)
Refused
1.26 (0.66-2.38)
No. of times of vaginal
intercourse in past three
a
months
None
1.00 (ref)
1 to 5
1.15 (0.51-2.61)
6 to 20
1.48 (0.79-2.78)
≥21
2.28 (1.30-4.01)
Refused
2.18 (1.03-4.61)
a
Ever had a partner with genital warts
No
1.00 (ref)
Yes
2.81 (1.21-6.48)
Don't know
2.89 (1.91-4.36)
Refused
2.48 (0.61-10.16)
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Ever been diagnosed with an
a
STI
No
Yes
Don't know
Refused

1.00 (ref)
1.00 (ref)
1.00 (ref)
2.52 (1.51-4.20)
1.99 (1.17-3.39)
2.11 (1.15-3.87)
0.47 (0.07-3.40)
0.34 (0.05-2.51)
0 (0-.)
2.02 (0.50-8.20)
1.46 (0.09-23.65)
1.10 (0.02-53.61)
Note: HR - hazard ratio; CI - confidence interval; bolded results have p-values <0.05.
a
Time-dependent covariates.
b
Includes men who only had sex with men in the last three months.
C
Each factor is adjusted for incident HPV 6/11 infection and all other variables in the table.
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CHAPTER 4: THIRD MANUSCRIPT: CONCORDANCE OF HUMAN
PAPILLOMAVIRUS TYPES DETECTED ON THE SURFACE AND IN THE TISSUE OF
CONDYLOMA IN MEN

ABSTRACT
The prevalence of HPV in condyloma has often been estimated by sampling the
lesion surface, however, HPV types on the lesion surface may not represent the types
present in the lesions themselves. We examined the concordance between HPV types
detected on the surface and in the tissue of condyloma in men. Samples obtained from
the surface of condyloma lesions were both sensitive and specific markers for the
presence of any HPV, HPV6 and HPV11 in condyloma tissue. Our results suggest that
sampling the surface of condyloma lesions is a non-invasive and accurate marker of the
HPV types present in condyloma tissue.

INTRODUCTION
Anogenital condyloma are the most common clinical manifestation of human
papillomavirus (HPV) infection [12]. Current standard practice is to diagnose condyloma
by visual inspection, and diagnosis is rarely confirmed by biopsy [25]. Thus, clinic-based
HPV prevalence studies use samples from the surface of condyloma lesions to estimate
the prevalence of HPV genotypes in the lesion tissue [26-28]. It is possible that the HPV
types detected on the surface of lesions may not represent the types present in the
lesions themselves. Accurate estimates of the distribution of HPV types in condyloma
are needed to model the efficacy of the quadrivalent HPV vaccine that protects against
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HPV 6, 11, 16 and 18 and for use in the development of future vaccines that protect
against additional HPV types.
Since biopsying anogenital condyloma is invasive and may deter individuals from
participating in studies that examine the prevalence of HPV types in anogenital lesions, it
is important to determine whether sampling the surface of a lesion provides an accurate
measure of the HPV types present within it. The purpose of this study was to examine
the concordance between HPV types detected on the surface and in the tissue of
condyloma and non-condyloma related genital lesions in men.

METHODS
Study participants and sample collection
Participants in this study were enrolled in the prospective HPV in Men (HIM)
Study that examined the natural history of HPV infection in men. To be eligible for
enrollment, men had to meet the following criteria(a) 18-70 years old; (b) resided in
Southern Florida, Sao Paulo, Brazil or the state of Morelos, Mexico; (c) reported no
previous diagnosis of penile or anal cancer; (d) reported no prior diagnosis of genital or
anal warts; (e) had not participated in an HPV vaccine clinical trial; (f) reported no prior
diagnosis of HIV or AIDS; (g) were not currently being treated for an STI; and (h) had
not been imprisoned, homeless or in drug treatment in the previous 6 months. A more
detailed description of procedures in the HIM Study has been published previously [3, 4,
35].
Men were examined by a trained clinician for the presence of external genital
lesions at clinic visits that occurred every six months over four years. Lesions that
exhibited clinical features suggestive of condyloma were sampled for the presence of
HPV DNA. A pre-wetted Dacron swab was used to sample the surface of the lesion and
a biopsy sample was also obtained. Lesions with unknown etiology were also sampled,
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although, lesions suspected to be non-HPV related such as Herpes Simplex Virus
lesions, pearly penile papules, molluscum contagiosum, skin tags, and sebaceous
glands were not sampled or biopsied. Healthy genital skin was also sampled by
combining swabs taken from the coronal sulcus/glans penis, penile shaft, and scrotum.
Lesions were sampled before the healthy skin to avoid inter-specimen contamination.
Patients with lesions suggestive of condyloma or dysplasia underwent removal by shave
excision. Excised tissue was placed in 10% buffered formalin and processed at the
University of South Florida Dermatopathology Laboratory for pathologic interpretation by
the study dermatopathologist, followed by DNA extraction for HPV genotyping.
HPV detection and genotyping
To test for the presence of HPV DNA in biopsied tissue, thin section microtomy
specimens were cut from formalin-fixed paraffin-embedded tissue samples. DNA was
extracted from the tissue slice, after removal of paraffin by boiling and digestion with
proteinase K, followed by precipitation of DNA with isopropanol using the QIAamp DNA
FFPE Tissue procedure (Qiagen Inc – USA). The INNO-LiPA HPV genotyping test
(Innogenetics) was used to test for the presence of 24 HPV genotypes including 13
oncogenic types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, and 66) and 11 nononcogenic types (6, 11, 40, 42, 43, 44, 53, 54, 68, 70, and 74).
DNA was extracted from swab samples of lesions and healthy skin samples
using the QIAamp Mini kit following the manufacturer’s instructions (Qiagen, Valencia,
CA). The polymerase chain reaction consensus primer system PGMY 09/11 was used
to amplify a fragment of the HPV L1 gene and test for the presence of HPV DNA. The
Linear Array HPV Genotyping Test (Roche Diagnostics, Indianapolis, IN) tested for the
presence of 37 HPV genotypes including 13 oncogenic types (16, 18, 31, 33, 35, 39, 45,
51, 52, 56, 58, 59, and 66) and 24 non-oncogenic types (6, 11, 26, 40, 42, 53, 54, 55,
61, 62, 64, 67-73, 81–84, IS39, and CP6108).
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A sample was considered HPV positive if HPV DNA was detected by PCR or
tested positive for at least one HPV genotype. Beta-globin was detected in 96% (47/49)
of biopsies and 92% (36/39) of surface swab specimens. The two biopsy samples
negative for β-globin included one condyloma and one benign squamous keratosis
lesion. The three swab samples from the surface of lesions negative for β-globin were
all benign squamous keratosis lesions. Samples that tested negative for β-globin were
not included in analyses.
Statistical analysis
The prevalence of individual HPV types was calculated as the proportion of men
who tested positive for each HPV type. Sensitivity, specificity, positive predictive value
(PPV), and negative predictive value (NPV) were calculated for individual HPV types to
measure the accuracy of sampling the surface of a lesion as a marker of the HPV types
present in the lesion tissue. Sensitivity was calculated as the proportion of lesions with
biopsy samples positive for a specific HPV type that also had swab samples from the
surface of the lesion positive for the same HPV type. Specificity was defined as the
proportion of biopsy samples negative for a specific HPV type that also had swab
samples negative for the same type. PPV was calculated as the proportion of lesions
with swab samples positive for an HPV type that also had a biopsy sample positive for
the same HPV type. NPV was the proportion of lesions with swab samples negative for
an HPV type that also had a biopsy sample negative for the same HPV type. Exact 95%
confidence intervals based on the binomial distribution were calculated for all
proportions. Analyses were restricted to the 20 HPV types tested for in both the surface
swab and biopsy samples (6, 11, 16, 18, 31, 33, 35, 39, 40, 42, 45, 51-54, 56, 58, 59,
66, and 68).
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RESULTS
In total, 34 lesions that tested β-globin positive for samples from both surface
swabs and biopsies were included in these analyses. The lesions included 19
histologically confirmed condyloma and 15 lesions that did not demonstrate specific
features of condyloma; diagnosis for these lesions was as follows: 13 benign squamous
keratosis , one seborrheic keratosis lesion and one lichenoid tissue reaction. The mean
ages of men with condyloma and non-condyloma lesions were 28 (range, 18-49) and 29
(range, 18-57), respectively.
Table 1 presents the prevalence of HPV types detected in samples obtained from
biopsies, the surface of lesions, and adjacent healthy genital skin for condyloma and
non-condyloma lesions. HPV DNA was detected in 95% of tissue samples obtained
from condyloma. The individual HPV types detected in the condyloma biopsies were
HPV6 (63%), HPV11 (32%), and HPV16 (11%). The prevalence of HPV DNA from
swab samples taken from the surface of the condyloma was also 95%. HPV6 (47%),
HPV11 (37%), HPV16 (16%), and HPV18 (11%) were the types most commonly
detected among condyloma swab samples. Other HPV types including 40, 51, 53, 56,
and 59 were detected on the surface of 26% of condyloma. All swab samples taken
from healthy genital skin adjacent to condyloma lesions were positive for HPV DNA.
Consistent with the biopsy and surface swab samples, HPV6 (42%), HPV11 (37%), and
HPV16 (26%) were the most common types detected, however, there was a higher
prevalence of other HPV types (47%) than was observed in the tissue or surface swab
samples.
HPV DNA was detected in 93% of tissue samples from non-condyloma lesions
with HPV6 (47%) and HPV11 (47%) being the most common types detected. Other
HPV types including 31, 33, 40, 51, 52, 53, and 58 were present in 20% of noncondyloma biopsies. Swab samples from the surface of non-condyloma lesions had
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lower prevalence for any HPV DNA (60%), HPV6 (27%), HPV11 (13%), and HPV16
(7%) than tissue samples.
Table 2 presents the sensitivity, specificity, PPV, and NPV of sampling the
surface of lesions and adjacent healthy skin as markers for the HPV types detected in
biopsy samples. The sensitivity of swab samples from any type of lesion as a marker for
HPV types in biopsied tissue for the corresponding lesion was 78% for any HPV, 63%
for HPV6, 62% for HPV11, 50% for HPV16, and 33% for other HPV types. Specificity of
swab samples of the lesions was also high for HPV6 (93%), HPV11 (95%), HPV16
(94%), and other HPV types (77%). Samples from the surface of condyloma lesions
were more sensitive than swabs from the surface of non-condyloma lesions for any HPV
(94% vs. 57%), HPV6 (75% vs.43%), and HPV11 (100% vs. 29%). Condyloma swabs
were less sensitive for HPV16 (50%). Swabs from both condyloma and non-condyloma
lesions were highly specific for HPV6 (100% and.88%), HPV11 (92% and 100%), and
HPV16 (88% and 100%). Non-condyloma lesion swabs were not sensitive (33%), but
were highly specific (83%) as markers of other HPV types in lesion tissue. Similar to
samples from the surface of lesions, swabs from adjacent healthy genital skin were more
sensitive for HPV types in condyloma tissue than non-condyloma tissue.
Among condyloma lesions there was high PPV for swabbing the surface of the
lesion for any HPV (94%), HPV6 (100%), and HPV11 (86%). High PPV signifies a low
rate of false positives for specific HPV types within the condyloma tissue when swabbing
the surface of the lesion. The frequency of false negatives was also low as indicated by
high NPV for HPV6 (70%) and HPV11 (100%).
When different lesion types (i.e., condyloma vs. non-condyloma) were classified
by visual inspection alone and not pathologically confirmed, 33 of the 34 lesions were
diagnosed as condyloma. Based on visual inspection, the sensitivity of swabbing the
surface of the lesion for any HPV (81%) and HPV type 6 (63%) and 11 (67%) was lower
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than among pathologically confirmed condyloma. Specificity of HPV types 6 (93%) and
11 (95%) however remained high among the condyloma diagnosed by visual inspection.

DISCUSSION
To our knowledge, this is the first study to examine the concordance between
HPV types detected on the surface and in the tissue of condyloma and non-condyloma
genital lesions in men. Swabs from the surface of condyloma were highly sensitive and
specific as markers for HPV types present in condyloma tissue. However, noncondyloma lesions were less sensitive markers of HPV types in lesion tissue and may
potentially underestimate the prevalence of individual HPV types within the lesion.
HPV DNA was detected in 95% of condyloma tissue samples from the current
study. This is consistent with previous studies that biopsied condyloma and reported
HPV prevalence estimates of 91% among women in the placebo arm of a vaccine trial
[24] and 100% of men and women seeking treatment in a standard clinic setting [33].
Likewise, HPV prevalence estimates ranged from 95% to 100% in studies that tested
samples from swabbing the surface of the condyloma [26-28]. Also similar to our
results, previous studies detected HPV 6/11 in 86% to 100% of condyloma [24, 26-28,
33]. The finding that HPV16 was the third most common type detected in condyloma
biopsies after HPV6 and HPV11 is consistent with previous studies that also reported a
high (≥25%) prevalence of HPV16 [24, 33]. Among condyloma lesions, the prevalence
of any HPV and types 6 and 11 was higher among the biopsy samples than samples
from the surface of the lesion. The sensitivities of the assays used to test the different
sample types may account for some of this difference. The INNO-LiPA assay used to
test the biopsy samples is more sensitive for detecting HPV than the Linear Array assay
used to test swabs from the surface of the lesion [44, 45], therefore prevalence of HPV is
more likely to be higher for biopsy samples.
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In this study, samples obtained from the surface of histologically confirmed
condyloma were sensitive markers for the presence of HPV in condyloma tissue.
However, in this study a significant number of lesions diagnosed as condyloma by visual
inspection were not confirmed histologically. In the current study, visual inspection was
94% sensitive and 23% specific for identifying histologically confirmed condyloma. This
apparent low specificity, however, likely relates to the difficulty of histologic diagnosis of
early condyloma, since the non-condyloma lesions had the same rate of HPV detection
by PCR as the condyloma lesions. A significant number of these non-condyloma (13/15,
87%) were given the diagnosis of “benign squamous keratosis,” a relatively non-specific
pathologic diagnosis for lesions that show some but not all of the diagnostic criteria for
HPV infection. It is compelling that swabs of these non-condyloma lesions were found to
be less sensitive as markers for the presence of HPV than the lesion tissue, a
phenomenon which may relate to low viral load of these pathologically subtle lesions.
Testing samples from the surface of condyloma diagnosed based on visual inspection
alone may slightly underestimate the prevalence of HPV genotypes in condyloma.
Small sample size is a limitation in our analyses and may have contributed to
the low sensitivity observed for some HPV types. Samples from the surface of
condyloma were only 50% sensitive to the presence of HPV16 in condyloma tissue.
Since only two condyloma biopsies tested positive for HPV16, a larger sample size with
a correspondingly higher prevalence of HPV16 might provide a more accurate measure
of sensitivity for this genotype. Given that most HPV genotypes were present in less
than 10% of lesions, we were not able to assess concordance for individual HPV types
other than 6, 11, and 16. Future studies should confirm our findings using a larger
sample size.
In summary, our results suggest that sampling the surface of a condyloma lesion
is a non-invasive and accurate marker of HPV types present in condyloma tissue.
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Therefore, it may not be necessary to add an invasive biopsy procedure to research
protocols for studying condyloma in a standard clinic setting.
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Table4.1. Prevalence of HPV genotypes in samples from biopsies, the surface of lesions, and adjacent healthy genital skin
for condyloma and non-condyloma genital lesions.
Biopsy samples

Samples from the surface of the lesion

NonHPV
condyloma
All lesions
All lesions
Condyloma
genotype
(N=15)
(N=19)
(N=34)
(N=34)
Any HPV
32 (94%)
18 (95%)
14 (93%)
27 (79%)
type
6
19 (56%)
12 (63%)
7 (47%)
13 (38%)
11
13 (38%)
6 (32%)
7 (47%)
9 (26%)
16
2 (6%)
2 (11%)
0 (0%)
3 (9%)
18
0 (0%)
0 (0%)
0 (0%)
3 (9%)
Other
HPV
a
3 (9%)
0 (0%)
3 (20%)
8 (24%)
types
a
Includes HPV 31, 33, 39, 40, 42, 51, 52, 53, 54, 56, 58, 59, and 66.
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Samples from adjacent healthy skin

Condyloma
(N=19)

Noncondyloma
(N=15)

All lesions
(N=34)

Condyloma
(N=19)

Noncondyloma
(N=15)

18 (95%)
9 (47%)
7 (37%)
3 (16%)
2 (11%)

9 (60%)
4 (27%)
2 (13%)
1 (7%)
1 (7%)

31 (91%)
12 (35%)
10 (29%)
6 (18%)
4 (12%)

19 (100%)
8 (42%)
7 (37%)
5 (26%)
2 (11%)

12 (80%)
4 (27%)
3 (20%)
1 (7%)
2 (13%)

5 (26%)

3 (20%)

16 (47%)

9 (47%)

7 (47%)

Table 4.2. Sensitivity, specificity, negative predictive value, and positive predictive value of samples from
the surface of lesions and adjacent healthy skin as markers of HPV types present in biopsy samples in
condyloma and non-condyloma genital lesions.
SWABS OF THE SURFACE OF THE LESION
SWABS OF ADJACENT HEALTHY SKIN
NonNonAll lesions
Condyloma
condyloma
All lesions
Condyloma
condyloma
(95% CI)
(95% CI)
(95% CI)
(95% CI)
(95% CI)
(95% CI)
Any HPV
Sensitivity
78 (60-91)
94 (73-100)
57 (29-82)
91 (75-98)
100 (81-100)
79 (49-95)
a
b
a
a
a
a
Specificity
n/a
n/a
n/a
n/a
n/a
n/a
PPV
93 (76-99)
94 (73-100)
89 (52-100)
94 (79-99)
95 (74-100)
92 (62-100)
b
NPV
100 (59-100)
n/a
100 (54-100)
93 (75-99)
95 (74-100)
92 (62-100)
HPV 6
Sensitivity
63 (38-84)
75 (43-95)
43 (10-82)
58 (34-80)
67 (35-90)
43 (10-82)
Specificity
93 (68-100
100 (59-100)
88 (47-100)
93 (68-100)
100 (59-100)
88 (47-100)
PPV
92 (64-100)
100 (66-100)
75 (19-99)
92 (62-100)
100 (66-100)
75 (19-99)
NPV
67 (43-85)
70 (35-93)
64 (31-89)
67 (43-85)
64 (31-89)
64 (31-89)
HPV 11
Sensitivity
62 (32-86)
100 (54-100)
29 (4-71)
69 (39-91)
100 (54-100)
43 (10-82)
Specificity
95 (76-100)
92 (64-100)
100 (63-100)
95 (76-100)
92 (64-100)
100 (63-100)
PPV
89 (52-100)
86 (42-100)
100 (16-100)
90 (56-100)
86 (42-100)
100 (16-100)
NPV
80 (59-93)
100 (74-100)
62 (32-86)
80 (59-93)
100 (74-100)
67 (35-90)
HPV 16
c
c
100 (16-100) 100 (16-100)
n/a
Sensitivity
50 (1-99)
50 (1-99)
n/a
Specificity
94 (79-100)
88 (64-99)
100 (78-100)
88 (71-96)
82 (57-96)
93 (68-100)
c
c
PPV
33 (1-91)
33 (1-91)
n/a
33 (4-78)
33 (1-91)
n/a
NPV
97 (83-100)
94 (70-100)
100 (78-100)
97 (83-100)
100 (77-100)
100 (77-100)
e
HPV Other
d
d
Sensitivity
33 (9-91)
n/a
33 (1-91)
33 (1-91)
n/a
33 (1-91)
Specificity
77 (59-90)
74 (49-91)
83 (52-98)
52 (33-70)
53 (29-76)
50 (21-79)
d
d
PPV
13 (0-53)
n/a
33 (1-91)
6 (0-30)
n/a
33 (1-91)
NPV
92 (75-99)
100 (77-100)
83 (52-98)
92 (75-99)
100 (69-100)
75 (35-97)
Note: CI - confidence interval; PPV – positive predictive value; NPV – negative predictive value.
a
Not calculated due to small numbers.
b
Not calculated because no men with condyloma had skin swabs negative for HPV.
c
Not calculated because HPV16 was not detected in any non-condyloma biopsies.
d
Not calculated because other HPV types were not detected in any condyloma biopsies.
e
Includes HPV 31, 33, 39, 40, 42, 51, 52, 53, 54, 56, 58, 59,and 66.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS

SUMMARY OF FINDINGS
This study examined the natural history of HPV related condyloma in a cohort of
2,487 men ages 18-70 from the US, Brazil, and Mexico enrolled in the prospective HIM
Study. This is one of the first studies to examine the progression from HPV infection to
condyloma development and prospectively assess the sexual behavioral factors
associated with condyloma in men.
The probability of developing a condyloma over 24-months was 5.2% and the
median time to condyloma detection was 17.1 months. HPV 6 and 11 were the HPV
types most strongly associated with development of condyloma. Men who had an
incident HPV 6/11 infection had 12 times the risk of developing condyloma compared to
men who were HPV negative. Men with incident HPV 6/11 infections also had the
highest probability of developing condyloma in a 24-month period (14.6%), and had the
shortest time to detection of condyloma (median of 6.2 months).
The surfaces of condyloma lesions were sampled to estimate the prevalence of
HPV types in the condyloma. HPV types 6, 11, and 16 were the most common types
detected, however, the HPV types detected on the surface of lesions may not represent
the HPV types present in the lesions themselves. Nineteen pathologically confirmed
condyloma with samples obtained from the surface of the lesion and biopsied tissue
were genotyped to assess the concordance between HPV types detected on the surface
and in the tissue of condyloma lesions. Sampling the surface of condyloma was both
highly sensitive and specific as a marker for the HPV types present in the condyloma
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tissue. Therefore, HPV prevalence estimates based on sampling the surface of lesions
are likely accurate estimate of the HPV types present in lesion tissue.
Recent sexual behavior was strongly associated with risk of developing
condyloma. Having three or more male anal sex partners in the previous three months
was associated with an almost five times greater risk of condyloma compared to men
with no male sexual partners. Frequent vaginal intercourse and infrequent condom use
during vaginal intercourse in the recent past also significantly increased the risk for
condyloma. Other factors associated with condyloma incidence were a high number of
lifetime female partners, having a partner with condyloma, and ever being diagnosed
with an STI. Younger age was also a significant risk factor; men who were older than
age 30 had a 50% reduced risk of condyloma compared to men ages 18-30.
Multicollinearity could be present in multivariable regression models if two or
more of the predictor variables in the model are highly correlated. A high amount of
multicollinearity would result in increased standard errors of the beta estimates and
subsequent wide confidence intervals. As a result, variables that are actually significant
predictors would appear to have no significant association with the outcome. The
Pearson correlation coefficient values between pairs of the variables included in the final
multivariable model (age, country, lifetime number of female partners, condom use,
recent number of male sexual partners, frequency of vaginal intercourse, having a
partner with condyloma, and having an STI) ranged from -0.02 to 0.21. Given that no
two variables in the model were highly correlated, it is not likely that a high degree of
multicollinearity was present in the final multivariable model examining the factors
associated with incident condyloma.
Eight hazard regression models were run using the same dataset to examine the
association between HPV infection with different HPV types and risk of condyloma. The
more HPV types that are examined in relation to condyloma risk, the greater the
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likelihood that there will be a significant association observed simply by chance (i.e.,
type 1 error) due to multiple comparisons. Multiple testing correction methods, such as
Bonferroni, require that a p-value smaller than 0.05 be observed to declare an
association is significant. Though correction for multiple comparisons was not included
in the models, a type 1 error is not likely given that the HRs for these models were very
high and the corresponding p-values were often <0.0001.
This study has limitations that need to be considered when interpreting the
results. Condyloma were identified by visual inspection and biopsy samples were not
obtained to confirm that lesions were true condyloma. Preliminary data from biopsy
results collected in the HIM Study showed that compared to the gold standard of
diagnosing condyloma by pathologic review, diagnosing condyloma by visual inspection
was highly sensitive (94%), but not very specific (23%). The low specificity suggests
that some of the condyloma included in these analyses were actually non-HPV related
skin conditions that resembled condyloma, such as benign squamous keratosis or
seborrheic keratosis. Despite the potential misclassification of diagnosing condyloma by
visual inspection, most previous studies also did not have pathologically confirmation
that lesions were condyloma. Another limitation is the generalizability of the findings is
likely limited due to the self-selection of participants. Men who agree to participate in a
four year prospective study may not be representative of the underlying population from
each country. However, our results are likely more generalizable than previous studies
that were based on populations of men who have sex with men or men who were
seeking treatment for an STI.
Despite limitations, there are strengths of the study to note as well. An extensive
risk factor questionnaire was used to collect data on multiple lifetime and recent sexual
behaviors. The prospective study design allowed for measuring changes in sexual
behavior over time. Repeated measures of behavior were important given that recent
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sexual behavior was strongly associated with risk of condyloma. The prospective study
design also allowed collection of data on sexual behavior before men developed
condyloma. Previous studies of risk factors for condyloma in men were case-control
studies that collected risk factor data after men were diagnosed with condyloma. This
could bias results if being diagnosed with condyloma caused men to alter their sexual
behavior (e.g., use condoms more frequently) or affected how accurately they recalled
their sexual habits. By collecting data on lifetime and recent sexual behavior before men
were diagnosed with condyloma, we were able to minimize the chance of recall bias.

FUTURE RESEARCH
This study was one of the first to examine incidence and risk factors associated
with condyloma in a prospective study largely including men from the general
community, however, there are limitations that need to be addressed in future studies.
The major limitation was identification of condyloma by visual inspection. Future studies
should biopsy suspected condyloma lesions to histologically confirm a lesion is
condyloma and thereby minimize misclassification. Condyloma incidence, time from
HPV infection to condyloma development, and risk factors for condyloma should then be
examined among histologically confirmed condyloma to assess if the results are
consistent with studies that relied on diagnosis by visual inspection.
Unclassified infections that tested positive for HPV DNA, but not for any specific
HPV genotypes, were observed in 5% of condyloma in this study. Cutaneous HPV
types may account for some of the unclassified infections observed, however, no studies
to date have utilized assays that test for the presence of cutaneous HPV in condyloma
samples. Futures studies should test for cutaneous in addition to mucosal HPV types in
an effort to identify the unclassified genotypes present in condyloma.
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The cohort used to examine risk factors for condyloma in this study included
heterosexual men and men who have sex with men. The placebo arm of an HPV
vaccine clinical trial of men observed a significantly higher incidence of condyloma in
men who have sex with men compared to men with only female sexual partners [14].
Future studies should assess incidence of condyloma stratified by sexual orientation and
examine whether the risk factors for condyloma differ between men who have sex with
men and men who have sex with women only. Differences in risk factors for condyloma
by sexual orientation may warrant different prevention strategies that focus on modifying
behavior in addition to vaccination.
Though condyloma are the most common clinical manifestation of anogenital
HPV infection, penile intraepithelial neoplasia (PIN), the pre-cursor lesion to
approximately 50% of invasive penile carcinomas, is another HPV related external
genital lesion that has not been studied extensively. Since these lesions have the
potential to develop into invasive cancer, it is important to identify risk factors associated
with incidence of these lesions to create appropriate prevention strategies. Accurate
estimates of the prevalence of HPV types in PIN lesions is also needed to model the
efficacy of the current HPV vaccine that protect against oncogenic HPV types 16 and 18.
Another area that needs further study is the role of HPV antibodies in protecting
against development of condyloma. Using archived serum samples from HIM Study
participants, a future study should examine whether HPV antibodies reduce the risk of
condyloma by comparing condyloma incidence between men who are sero-negative and
sero-positive for different HPV types.
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APPENDIX A: LITERATURE REVIEW
Human Papillomavirus
Human papillomavirus (HPV) is the most common sexually transmitted infection
in the United States, with an estimated 6.2 million new cases each year [1]. HPV is an
established cause of cervical cancer and its precursor lesion, cervical intraepithelial
neoplasia (CIN). The virus is also known to be associated with cancers at other sites
including the oropharynx, anus, penis, vulva and vagina [2]. HPV related external
genital lesions (EGL) in men include genital warts and penile intraepithelial neoplasia
(PIN), a precursor lesion to some penile carcinomas.
Over 100 HPV types have been identified and approximately 40 of these types
infect the anogenital region. HPV types are classified as non-oncogenic types (e.g. 6
and 11) that are associated with benign conditions such as genital warts, and oncogenic
types (e.g. 16, 18, 45, and 31) that are associated with intraepithelial neoplasia and
invasive carcinoma. The majority of HPV infections are asymptomatic and 70% of
infections with clear within 12 months, however persistent infections can progress to
dysplasia or invasive carcinoma [3].
The quadrivalent vaccine Gardasil, that protects against HPV types 6, 11, 16,
and 18, is currently available to women, and is effective at reducing the incidence of
genital warts and precancerous lesions of the cervix, vulva and vagina [4]. In October
2009, the U.S. Food and Drug Administration approved the use of Gardasil in men ages
9 to 26. The vaccine is currently being tested among men and has shown to be effective
at reducing the incidence of HPV infection and genital warts in men ages 16-26 [5].
Vaccinating men may also reduce the incidence of HPV related penile dysplasia and
penile carcinoma. More data on HPV type distribution of male genital lesions and time
from HPV infection to lesion development are needed to assess the potential impact of a
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prophylactic vaccine in men, and to develop future vaccines that protect against
additional HPV types.
To date, most research on the progression of HPV infection to disease has
focused on women. Little is known about the natural history of HPV related disease in
men, including the HPV types associated with lesions, the rate of progression from HPV
infection to lesion development, the proportion of type-specific HPV infections that
progress to lesions and the sociodemographic and sexual behavior factors associated
with the development of lesions. Since male genital lesions are reservoirs for HPV
infection, understanding the natural history of HPV related genital disease in men has
the potential to not only reduce the burden of male disease, but also reduce the rate of
HPV transmission to women.
Genital HPV Infection in Men
A recent systematic review reported the prevalence of genital HPV DNA among
men ranging from 1.3%-72.9% (with most studies reporting ≥20%) [6]. HPV prevalence
varies widely across studies due to differences in the populations studied, genital sites
sampled (e.g., scrotum, shaft, glans, etc.), and HPV DNA detection methods used.
Prevalence tends to be higher in studies that use more sensitive DNA detection methods
or sample for HPV DNA at multiple sites on the genitalia. There are also differences
across studies in the number of HPV types tested for. Some studies only tested for HPV
types 16 and 18, while other studies utilized assays that could detect more than 30 HPV
types.
The multi-national HIM study (the source of the lesion data for this study)
reported an overall HPV prevalence of 65.1% with a statistically significant higher
prevalence in Brazil (72.3%) than the US (61.3%) or Mexico (61.9%) [7]. The HIM study
prevalence estimate is based on sampling from four anatomic sites (coronal sulcus,
glans, shaft, and scrotum) and testing for the presence of 37 types of HPV. Among
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men with HPV infections, 12.0% had oncogenic types only, 20.7% had non-oncogenic
types only, 17.8% had both oncogenic and non-oncogenic types, and 14.7% had
unclassified types only (tested positive for HPV by PCR, but negative for all of the 37
mucosal HPV types tested for). There was also a high rate of multiple infections
(25.7%). HPV 6 (6.6%) and HPV 16 (6.5%) were among the most common types, while
HPV 11 (1.5%) and HPV 18 (1.7%) were detected less frequently. Similar results were
seen in a cross-sectional study of US men that examined HPV prevalence at six
anogenital sites (glans/corona, penile shaft, scrotum, urethra, perianal area and anal
canal) [8]. HPV was detected in 65.5% of men, with half the men (51.2%) testing
positive for a known oncogenic or non-oncogenic type and another 14.3% testing
positive for an unclassified HPV type. HPV 16 was the most common type detected
(11.4%).
Only a few cohort studies have examined the incidence and duration of HPV
infection in men [9-14]. It is estimated that the cumulative incidence of male HPV
infection over a 12-month period is between 29% and 39% [13, 14]. The majority of
infections clear in less than 12 months, with one study of US men reporting a median
time to clearance of 5.9 months [15].
The factors independently associated with HPV infection in men include not
being circumcised [12, 15-18], lack of condom use [19-21], a history of having ever
smoked [17, 19, 21], and a high number of lifetime sexual partners [15, 16, 19-21].
Smoking impairs the humoral immune response (i.e., development of antibodies) to HPV
infection [22]. An impaired immune response can increase the risk of becoming infected
after being exposed to HPV or increase the likelihood of developing a persistent HPV
infection. Being circumcised may reduce the risk of infection by increasing the amount
of keratinized epithelium present, which provides a more protective barrier than mucosal
tissue against HPV infection. Men who are not circumcised have a greater risk of micro
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tears or abrasions (portals of entry for HPV) when the mucosal lining of the foreskin is
exposed during intercourse [23].
There does not appear to be an association between age and HPV prevalence in
men. Studies consistently show that prevalence of HPV infection in men remains
constant over the lifetime [6, 15, 19]. This is in contrast to the pattern observed in
women, where HPV prevalence is highest among women 18-24 and then decreases
until middle age, after which it remains steady for the remainder of the lifespan [24].
Epidemiology of Genital Warts
Genital warts are a common sexually transmitted disease in the US, with an
estimated 1 million new cases each year [25]. Data from private health plans estimate
that the prevalence of genital warts is highest among men ages 25-29 and decreases
with age [26]. Though there are no national data on the prevalence of genital warts in
the US, in the 1999-2004 National Health and Nutrition Examination Survey, 5.6% of
sexually active adults ages 18-59 reported having ever been diagnosed with genital
warts (7.2% women and 4.0% men) [27]. There are no precise estimates of genital wart
incidence among men in the US.
Though genital warts are benign and not associated with mortality, they are a
source of psychosocial distress, such as shame and embarrassment [28]. On rare
occasions they can develop into malignant conditions such as Buschke–Lowenstein
tumors or penile carcinoma [29]. Approximately 20-30% of genital warts will
spontaneously regress [30], however recurrence of warts is common, resulting in high
medical costs for repeated treatment. An estimated $200 million is spent annually in the
US for direct medical costs of genital wart treatment [31].
The incubation period is 3 weeks to 8 months, with most warts developing 2-3
months after infection with HPV [32]. Genital warts are highly infectious and
approximately 65% of people whose sexual partner has genital warts will develop warts

62

themselves [32]. Circumcised men are more likely to report a history of genital warts
(4.5%) than uncircumcised men (2.4%) [27]. This is opposite from the association
observed with HPV infection, where circumcised men are less likely to have HPV. A
possible explanation is that the uncircumcised men failed to detect genital warts that
developed under the foreskin. Among sexually active adults in the US, people who had
>10 sexual partners in their lifetime had more than 7 times the odds of reporting a history
of genital warts compared to adults with only 1 or 2 lifetime partners (OR=7.6; 95% CI:
4.1-13.9) [27].
HPV and Genital Warts
More than 90% of genital warts are caused by non-oncogenic HPV types 6 and
11 [29]. Data available for the HPV type distribution of genital warts in men are sparse.
The largest case series to look at a broad range of HPV types in male genital warts
included 135 men from Hong Kong [33]. HPV DNA was detected in 96% of the warts.
Among HPV positive warts, 75.4% had non-oncogenic types only, 3.8% had oncogenic
types only, and 20.8% had both oncogenic and non-oncogenic types. There was a high
rate of multiple infections (33.8%), often including coinfection with oncogenic types.
HPV 6 was the most common type detected (54.6%), followed by HPV 11 (40.8%) and
HPV 16 (6.2%). A smaller case series of 12 men detected HPV in 100% of genital
warts. Again, the most common HPV types were HPV 6 (75.0%), HPV 11 (16.7%) and
HPV 16 (8.3%) [34].
HPV 6/11 have consistently been the most common types detected in genital
warts. Previous studies reported the HPV 6/11 prevalence in genital warts to be 86%
among young women in the placebo arm of an HPV vaccine trial [35], 89% in men from
Hong Kong [33], 90% among French men ages 18-72 [36], and greater than 95% in two
small US studies that included fewer than 50 men [37, 38]. Oncogenic HPV types have
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also commonly been detected in genital warts and several studies reported a high
prevalence of HPV 16 [33, 35, 36, 38].
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